ACIU
AC Immune S.A.
ACIU has lower modeled downside risk, despite its lower overall score.
OSCR
Oscar Health, Inc.
OSCR has the edge over ACIU overall, supported by stronger fundamentals and stronger modeled upside.
ACIU Fundamentals
| Metric | Status |
|---|---|
| Under pressure | |
| Weak | |
| Under pressure | |
| Strong |
ACIU's balance sheet is currently strong, but its revenue, profitability and cash flow are under pressure.
OSCR Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Healthy | |
| Strong | |
| Strong |
OSCR's revenue, profitability, cash flow and balance sheet are all currently healthy.
ACIU PE Valuation
ACIU has no meaningful PE right now: it lost money over the past year.
OSCR PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 12x | $31.94 | — |
| Current | 13x | $31.94 | — |
| Cheap | 21x | $52.73 | +65% |
| Fair | 35x | $87.23 | +173% |
| Expensive | 130x | $322 | +907% |
Historical ranges are pointers, not guarantees.
OSCR's PE is 13x, but its earnings don't support one, so it isn't a reliable read right now.
ACIU Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Returning to profit | |
| Strong growth | |
| -- | |
| Limited | |
| High |
Analysts expect ACIU to return to profit, with revenue growing.
OSCR Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect strong earnings and revenue growth for OSCR, with profitability improving.
ACIU Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q2 2026 | -$0.52 | +$0.08 |
| Q1 2026 | -$0.79 | -$0.16 |
| Q4 2025 | -$0.84 | -$0.23 |
| Q3 2025 | -$0.85 | -$0.35 |
| Q2 2025 | -$0.60 | +$0.18 |
| Q1 2025 | -$0.63 | +$0.11 |
| Q4 2024 | -$0.61 | +$0.17 |
| Q3 2024 | -$0.50 | +$0.48 |
ACIU is still losing money, but far less than before: $0.52 per share over the past year, against $1.23 at its worst in mid-2021.
OSCR Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $2.61 | +5.6% |
| Q3 2026 | $2.47 | +$3.47 |
| Q2 2026 | $1.45 | +$2.14 |
| Q1 2026 | -$0.54 | -235% |
| Q4 2025 | -$1.69 | -1790% |
| Q3 2025 | -$1.00 | -$0.92 |
| Q2 2025 | -$0.69 | -$0.54 |
| Q1 2025 | $0.40 | +$0.82 |
| Q4 2024 | $0.10 | +$1.32 |
OSCR has the edge over ACIU on earnings quality, reporting a profit while its opponent remains loss making.
ACIU Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $18.2M | +1057% |
| Q1 2026 | $1.3M | +13% |
| Q4 2025 | $406.9K | -70% |
| Q3 2025 | $1.1M | -96% |
| Q2 2025 | $1.6M | +90% |
| Q4 2024 | $1.4M | -92% |
| Q4 2023 | $17.8M | +1479813% |
| Q4 2020 | $1.1M | +9.8% |
ACIU's revenue is recovering but still below its 2019 peak: $18M last quarter, up 1057% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | 7.9% | +1492 points |
| Q1 2026 | -1322% | +635 points |
| Q4 2025 | -4262% | -2625 points |
| Q3 2025 | -1722% | -1750 points |
| Q2 2025 | -1485% | +1567 points |
| Q1 2025 | -1957% | N/A |
| Q4 2024 | -1637% | -1614 points |
| Q3 2024 | 29% | N/A |
ACIU has the edge over OSCR on profitability, with a higher operating margin.
OSCR Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $5.1B | +72% |
| Q2 2026 | $4.9B | +70% |
| Q1 2026 | $4.6B | +53% |
| Q4 2025 | $2.8B | +17% |
| Q3 2025 | $3B | +23% |
| Q2 2025 | $2.9B | +29% |
| Q1 2025 | $3B | +42% |
| Q4 2024 | $2.4B | +67% |
OSCR has the edge over ACIU on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 3.5% | +7.8 points |
| Q2 2026 | 8% | +16 points |
| Q1 2026 | 15% | +5.4 points |
| Q4 2025 | -12% | -5.7 points |
| Q3 2025 | -4.3% | -2.3 points |
| Q2 2025 | -8.1% | -11 points |
| Q1 2025 | 9.8% | +1.1 points |
| Q4 2024 | -6.2% | +4 points |
OSCR's operating margin was 3.5% last quarter, up 7.8 points from the same quarter a year ago.
ACIU Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | $0 | +$19.2M |
| Q1 2026 | $0 | +$23.1M |
| Q4 2025 | -$19.9M | -383% |
| Q3 2025 | -$22.1M | -$4.9M |
| Q2 2025 | -$19.2M | -122% |
| Q1 2025 | -$23.1M | -2575% |
| Q4 2024 | $7M | +$26.7M |
| Q3 2024 | -$17.2M | -$881.2K |
ACIU has burned cash in most quarters: −$42M over the past year, against −$53M the year before.
OSCR Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$1.2B | -$238.2M |
| Q2 2026 | $2.1B | +316% |
| Q1 2026 | $2.6B | +200% |
| Q4 2025 | $662.8M | +95% |
| Q3 2025 | -$973.7M | -$466M |
| Q2 2025 | $499.8M | +2.1% |
| Q1 2025 | $869.5M | +38% |
| Q4 2024 | $340M | +17% |
OSCR has the edge over ACIU on cash generation, producing positive trailing cash flow while its opponent burns cash.
ACIU Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | 0% | -- |
| 1 year | -1.9% | -2M shares |
| 3 years | +17% | +14.5M shares |
| 5 years | +34% | +25M shares |
| Available history | +37% | +26.4M shares |
ACIU has the edge over OSCR on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q2 2026 | — |
| Q1 2026 | — |
| Q4 2025 | — |
| Q3 2025 | — |
| Q2 2025 | — |
| Q1 2025 | $6,019 |
| Q4 2024 | — |
| Q3 2024 | — |
ACIU hasn't bought back shares in the past year.
OSCR Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +3.9% | +13M shares |
| 1 year | +34% | +87.2M shares |
| 3 years | +55% | +123M shares |
| 5 years | +66% | +138M shares |
| Available history | +71% | +143M shares |
OSCR has 346M diluted shares, up 34% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2020 | — |
| Q3 2020 | — |
| Q2 2020 | — |
| Q1 2020 | — |
ACIU Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q4 2019 | -4.3x | Net Cash |
| Q3 2019 | -4.3x | Net Cash |
ACIU has more cash than debt.
OSCR Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -4.2x | Net Cash |
| Q2 2026 | -5.5x | Net Cash |
| Q1 2026 | -110.0x | Net Cash |
| Q1 2025 | -9.7x | Net Cash |
| Q4 2024 | -13.7x | Net Cash |
| Q3 2024 | -10.1x | Net Cash |
| Q2 2024 | -24.0x | Net Cash |
| Q1 2024 | -217.7x | Net Cash |
OSCR has more cash than debt.
ACIU Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 40.0 | Neutral |
| Stochastic | 18.0 | Oversold |
ACIU's weekly RSI is 40 (neutral) and its Stochastic is 18 (oversold).
OSCR Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 58.7 | Neutral |
| Stochastic | 44.9 | Neutral |
OSCR's weekly RSI is 59 (neutral) and its Stochastic is 45 (neutral).
ACIU PE vs Healthcare Sector
| Metric | ACIU | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
ACIU has no meaningful PE right now: it lost money over the past year.
OSCR PE vs Healthcare Sector
| Metric | OSCR | Sector median | Relative |
|---|---|---|---|
| PE | 13x | 26x | 50% below |
| PE % | 3 | 35 | 32 pts below |
OSCR is trading at 13x earnings, a 50% discount to the Healthcare sector's median of 26x, though its earnings don't support one.
ACIU Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $2.39 | 10% below |
| 20 week MA | $2.47 | 13% below |
| 50 week MA | $2.74 | 22% below |
| 100 week MA | $2.57 | 17% below |
| 200 week MA | $2.81 | 24% below |
ACIU is in a downtrend: it's below all five of its weekly moving averages, and 24% below its 200-week average.
OSCR Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $31.2 | 2.3% above |
| 20 week MA | $31.1 | 2.8% above |
| 50 week MA | $22.9 | 39% above |
| 100 week MA | $19.3 | 65% above |
| 200 week MA | $15.5 | 106% above |
OSCR has the edge over ACIU on trend strength, trading above more of its moving averages.
ACIU Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $8.39 | $5.51 | -34% |
| 2021 | $5.51 | $5.39 | -2.2% |
| 2022 | $5.39 | $1.75 | -68% |
| 2023 | $1.75 | $5.00 | +186% |
| 2024 | $5.00 | $2.73 | -45% |
| 2025 | $2.73 | $3.13 | +15% |
| 2026 YTD | $3.13 | $2.14 | -32% |
ACIU's yearly returns have swung widely, from +186% in 2023 to −68% in 2022. It's down 32% so far in 2026.
OSCR Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $31.0 | $8.02 | -74% |
| 2022 | $8.02 | $2.21 | -72% |
| 2023 | $2.21 | $9.15 | +314% |
| 2024 | $9.15 | $13.8 | +51% |
| 2025 | $13.8 | $14.9 | +8% |
| 2026 YTD | $14.9 | $31.9 | +114% |
OSCR has the edge over ACIU on returns for 2026, with the stronger performance.